Linagliptin but not sitagliptin inhibited transforming growth factor-beta2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition
"A concerning trend [is that] the blatant openness of medication use of celebrities, former elite athletes and non-celebrity folk may be well intended to reduce stigma and shame
Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
McGraw-Hill / Lange rxlist.com (Tragenta ) Alogliptin Trade Name: Nesina Mechanism of Action: a DPP-4 inhibitor, similar to Sitagliptin Pharmacokinetics: does not undergo significant metabolism, and is mostly excreted unchanged in the urine (76%) and feces (13%) dosage should be reduced in patients with moderate to severe renal impairment References: Masharani U, Kroon L (2024): Pancreatic Hormones & Antidiabetic Drugs (Chapter 41)
As demand, accessibility and affordability increase, its likely the number of users will rise and its important for them to be informed
These CVOTs have collectively contributed significantly to our understanding of the cardiovascular outcomes related to GLP-1 receptor agonists
